5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …

Radiotherapy remains the foundation of current treatment for patients with locally advanced
squamous cell carcinoma of the head and neck (SCCHN). It has been shown that the …

Purpose: Treatment with cisplatin or cetuximab combined with radiotherapy each yield
superior survival in locally advanced squamous cell head and neck cancer (LA-SCCHN) …

Background We conducted a multinational, randomized study to compare radiotherapy
alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

Squamous cell carcinoma of the head and neck (HNSCC) while curable in many cases with
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …

The treatment of locoregionally advanced squamous cell carcinoma of the head and neck
(SCCHN) has evolved in recent years as a consequence of a better understanding of the …

Purpose Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth
factor receptor. Cetuximab has activity in squamous cell carcinoma and enhances both …

Approximately 600,000 new cases of head and neck cancer arise worldwide each year. Of
these, a large majority are head and neck squamous cell carcinomas (HNSCC) …

The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …